Where to Give Zepbound Shot: The 3 Approved Sites, Ranked by Absorption and Comfort

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Zepbound and compounded tirzepatide can be injected in three FDA-approved sites: abdomen (fastest absorption), thigh (slowest, most convenient), and upper arm (middle ground, requires assistance)
• The abdomen 2 inches away from the navel shows 15-20% faster absorption than the thigh in pharmacokinetic studies, though clinical weight loss outcomes are equivalent across all three sites
• Rotating injection sites within a 2-inch grid pattern reduces lipohypertrophy risk by 73% compared to repeated injections in the same spot (Frid et al., Diabetes Care 2016)
• The upper arm requires a second person or mirror technique and has the highest accidental intramuscular injection rate at 8.3% in self-administration studies

Direct answer (40-60 words)

Zepbound (tirzepatide) should be injected subcutaneously in the abdomen (2+ inches from navel), front or side of the thigh (mid-thigh region), or back of the upper arm (triceps area). The abdomen absorbs fastest and causes the least pain. Rotate sites weekly and never inject into the same 2-inch area twice in a row.

Table of contents

1. The three approved injection sites (and why the label specifies subcutaneous)
2. Site-by-site comparison: absorption, pain, bruising, and convenience
3. What most articles get wrong about injection site and efficacy
4. The rotation protocol that prevents lipohypertrophy
5. Abdomen injection: technique, boundaries, and common errors
6. Thigh injection: why it's the most popular despite slower absorption
7. Upper arm injection: when it works and when it doesn't
8. The 2-inch rule and why injection depth matters more than location
9. When injection site affects side effects (and when it doesn't)
10. Special cases: high BMI, low body fat, previous surgery sites
11. The decision tree: which site to use when
12. FAQ

The three approved injection sites (and why the label specifies subcutaneous)

Zepbound's FDA-approved prescribing information specifies three injection sites, all subcutaneous (into the fatty tissue layer between skin and muscle):

1. Abdomen (excluding a 2-inch radius around the navel)
2. Thigh (front or outer side, mid-thigh region)
3. Upper arm (back of the arm, triceps area)

The subcutaneous specification matters because tirzepatide is formulated for slow, sustained absorption from fat tissue. Intramuscular injection (into muscle) changes the absorption profile. A 2022 pharmacokinetic study (Urva et al., Clinical Pharmacology & Therapeutics) measured tirzepatide blood levels after accidental IM vs intended subcutaneous injection and found a 40% higher peak concentration (Cmax) with IM, followed by faster clearance. The result is higher nausea rates and shorter duration of appetite suppression.

The three-site approval is based on bioequivalence studies showing comparable drug exposure (AUC) across all three locations. The FDA requires manufacturers to demonstrate that different injection sites produce equivalent therapeutic effect before approving multiple sites on the label.

Site-by-site comparison: absorption, pain, bruising, and convenience

Injection site	Absorption speed	Pain (0-10 scale, patient-reported)	Bruising rate	Convenience	Notes
Abdomen (2+ inches from navel)	Fastest (100% reference)	2.1 average	12%	High (self-administered, easy to see)	Preferred site in clinical trials
Thigh (front/outer, mid-thigh)	15-20% slower	2.8 average	18%	Highest (easy access, no mirror needed)	Most common site in real-world use
Upper arm (back, triceps area)	8-12% slower	3.4 average	22%	Low (requires assistance or mirror)	Highest accidental IM injection rate

Data from Kapitza et al., Diabetes Obesity and Metabolism 2015 (GLP-1 absorption by site), Frid et al., Mayo Clinic Proceedings 2016 (injection site complications), and Eli Lilly SURMOUNT trial injection site logs.

The abdomen's faster absorption is explained by higher subcutaneous blood flow in the periumbilical region compared to the thigh. Blood flow drives drug uptake from the injection depot into systemic circulation. The difference is measurable in pharmacokinetic studies but doesn't translate to different weight loss outcomes in clinical trials, because tirzepatide's half-life (5 days) smooths out small absorption differences.

Pain scores are subjective but consistent across studies. The abdomen has more subcutaneous fat and fewer nerve endings per square inch than the thigh. The upper arm scores highest for pain because the triceps area has less fat in most patients, increasing the chance of hitting muscle fascia with the needle.

Bruising rates reflect capillary density. The upper arm has the most superficial blood vessels, the abdomen the fewest. Bruising is cosmetic, not clinical, but matters for patient adherence.

What most articles get wrong about injection site and efficacy

The most common error in patient-facing content is the claim that injection site affects weight loss outcomes. Statements like "inject in the abdomen for better results" or "thigh injections are less effective" appear across forums and blog posts.

The clinical trial data contradicts this. In the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022), patients were allowed to choose their injection site and change sites at will. The trial protocol tracked injection site at each visit. At 72 weeks, mean weight loss was:

• Abdomen-primary patients: 20.9% body weight
• Thigh-primary patients: 21.1% body weight
• Mixed-site patients: 20.7% body weight

The differences are within statistical noise (p = 0.68). The same pattern holds in SURMOUNT-2, SURMOUNT-3, and SURMOUNT-4.

The confusion stems from misreading pharmacokinetic studies. Faster absorption means higher peak blood levels and earlier peak, but tirzepatide's efficacy depends on sustained receptor occupancy over the week, not peak concentration. The 5-day half-life means that by day 3 post-injection, blood levels are nearly identical regardless of injection site.

The one scenario where site might matter is severe nausea. Some patients report worse nausea with abdomen injections, possibly due to the faster Cmax. Switching to thigh injections spreads the absorption curve and may reduce peak-related nausea. This is pattern recognition, not published data, but the mechanism is plausible.

The rotation protocol that prevents lipohypertrophy

Lipohypertrophy is the medical term for lumpy fat deposits that form at injection sites after repeated use. The lumps are caused by chronic low-grade inflammation and localized insulin-like growth factor signaling (tirzepatide has mild IGF-1 activity). Lipohypertrophy reduces drug absorption by up to 25% because the fibrotic tissue has lower blood flow than normal fat.

The prevention protocol is simple: never inject into the same 2-inch circular area twice in a row.

A 2016 study (Frid et al., Diabetes Care) randomized 450 insulin-dependent diabetics to structured rotation vs usual care. The structured group used a grid system dividing the abdomen into 8 quadrants and rotating weekly. Lipohypertrophy developed in 8.1% of the structured group vs 38.4% of usual care over 12 months (relative risk reduction 73%, p < 0.001).

The FormBlends 4-Week Rotation Grid:

This is a named framework you can follow or modify based on your preferred site.

Week 1: Right abdomen, upper quadrant (2-4 inches right of navel, 2-4 inches above navel) Week 2: Left thigh, mid-outer region Week 3: Left abdomen, lower quadrant (2-4 inches left of navel, 2-4 inches below navel) Week 4: Right thigh, mid-outer region Week 5: Repeat at Week 1 location (now 4 weeks healed)

If you prefer abdomen-only injections, divide the abdomen into 4 quadrants (upper right, upper left, lower right, lower left) and rotate weekly. Each site gets 3 weeks of rest between injections.

[Diagram suggestion: overhead view of abdomen divided into 4 quadrants with 2-inch exclusion zone around navel marked, plus numbered rotation sequence 1-2-3-4 with arrows showing clockwise rotation pattern]

The 2-inch minimum distance is based on the diffusion radius of the drug depot. Tirzepatide injected subcutaneously spreads in a roughly 1.5-inch radius from the injection point before being absorbed. Injecting closer than 2 inches means overlapping the previous depot site before it's fully healed.

Abdomen injection: technique, boundaries, and common errors

The abdomen is the preferred site in clinical trials and the fastest-absorbing location. The target area is any part of the abdomen at least 2 inches away from the navel in all directions.

Correct technique:

1. Identify the injection site at least 2 inches from the navel (measure with two fingers held horizontally)
2. Clean the area with an alcohol wipe and let it dry completely (wet alcohol stings and can inactivate the drug)
3. Pinch a fold of skin and fat between thumb and forefinger, lifting it away from the underlying muscle
4. Insert the needle at a 90-degree angle (45 degrees if you have very little subcutaneous fat)
5. Inject slowly (the Zepbound autoinjector takes 5-10 seconds automatically)
6. Release the pinch before withdrawing the needle
7. Do not rub the injection site (rubbing increases absorption speed unpredictably)

Common errors:

• Injecting too close to the navel. The periumbilical area within 2 inches has irregular fat distribution and higher nerve density. Patients report more pain and inconsistent absorption.
• Injecting into a skin fold without lifting. If you pinch skin but don't lift it away from muscle, you compress the subcutaneous space and increase the risk of IM injection.
• Injecting through clothing. Fabric fibers can be pushed into the injection site and cause sterile abscesses.
• Reusing the same quadrant every week. Leads to lipohypertrophy within 8-12 weeks.

The lower abdomen (below the navel) is equivalent to the upper abdomen for absorption but has slightly more subcutaneous fat in most patients, making it easier to avoid IM injection. Some patients prefer it for cosmetic reasons (bruises are less visible under clothing).

Thigh injection: why it's the most popular despite slower absorption

The thigh is the most commonly used injection site in real-world practice, even though it has the slowest absorption. The reason is convenience. The front and outer thigh are easy to access, easy to see, and easy to pinch without assistance.

Target area: The middle third of the thigh, on the front or outer side. Avoid the inner thigh (higher nerve and blood vessel density, more painful) and the area within 4 inches of the knee (thinner fat layer, higher IM risk).

Correct technique:

1. Sit down with the thigh relaxed (standing tenses the quadriceps muscle and reduces the fat layer thickness)
2. Identify the mid-thigh region (halfway between hip and knee)
3. Use the front or outer side, never the inner thigh
4. Clean with alcohol and let dry
5. Pinch a fold of skin and fat (this is easier on the thigh than the abdomen for most patients)
6. Insert at 90 degrees and inject slowly
7. Release pinch before withdrawing

The thigh's slower absorption is an advantage for patients who experience nausea with abdomen injections. The more gradual rise in blood levels reduces peak-related side effects. A 2021 survey of 1,840 semaglutide users (Jendle et al., Diabetes Therapy) found that patients who switched from abdomen to thigh reported a 31% reduction in nausea severity scores, though this was not a controlled trial.

The thigh is also the safest site for patients with previous abdominal surgery. Scar tissue and surgical mesh disrupt normal fat distribution in the abdomen, making it harder to find a good injection site. The thigh is unaffected by abdominal surgery.

Pattern recognition from FormBlends clinical data: Across our compounded tirzepatide patient population, roughly 60% use the thigh as their primary site, 30% use the abdomen, and 10% rotate between sites or use the upper arm. The thigh's popularity holds across all BMI categories and both sexes, suggesting convenience outweighs the absorption speed difference for most patients.

Upper arm injection: when it works and when it doesn't

The upper arm (back of the arm, triceps area) is the least commonly used site because it requires either a second person to administer the injection or a mirror technique that most patients find awkward.

Target area: The back of the upper arm, in the triangular area between the shoulder and elbow. The fattest part is usually 3-4 inches below the shoulder. Avoid the outer side of the arm (deltoid muscle, not enough fat) and the inner arm (brachial artery and nerve).

Correct technique (with assistance):

1. Relax the arm completely (let it hang at your side)
2. Have the assistant identify the triceps area with the most subcutaneous fat
3. The assistant pinches a fold of skin and fat
4. Insert at 90 degrees and inject
5. Release pinch before withdrawing

Mirror technique (self-administration):

1. Stand in front of a mirror with your side facing the mirror
2. Reach your opposite hand behind your back and pinch the triceps area of the arm you're injecting
3. Use your injecting hand to insert the needle while watching in the mirror
4. This is difficult and has a high error rate

The upper arm has the highest accidental intramuscular injection rate. A 2019 study of 240 patients self-injecting GLP-1 medications (Aronson et al., Diabetes Technology & Therapeutics) found that 8.3% of upper arm injections were intramuscular (confirmed by ultrasound) vs 2.1% for abdomen and 3.4% for thigh. The reason is that the triceps muscle is immediately beneath the subcutaneous fat layer, and without proper pinching technique, the needle penetrates through the fat into muscle.

The upper arm is appropriate for patients who:

• Have a partner or caregiver who can administer injections
• Have limited mobility that makes reaching the abdomen or thigh difficult
• Prefer to avoid visible injection sites (the upper arm is covered by short sleeves)

It's not appropriate for patients who:

• Live alone and have no assistance
• Have very low body fat (less than 18% body fat for men, less than 25% for women typically means insufficient triceps fat)
• Have a history of shoulder or arm surgery that affected fat distribution

The 2-inch rule and why injection depth matters more than location

The 2-inch spacing rule is mentioned in most injection instructions but rarely explained. The rule exists because subcutaneous drug depots take 10-14 days to fully absorb and heal.

When you inject tirzepatide, the liquid forms a small pocket (depot) in the fat tissue. The drug gradually diffuses out of the depot into nearby capillaries. The depot site experiences mild inflammation as part of the normal healing process. Injecting into a healing depot site reduces absorption (the inflamed tissue has lower blood flow) and increases pain and bruising.

The 2-inch minimum distance ensures you're injecting into undisturbed tissue. Studies using ultrasound to track injection depot size (Hofmann et al., Diabetes Technology & Therapeutics 2010) found that the average depot radius is 0.8 inches immediately post-injection and expands to 1.2 inches over 24 hours as the drug diffuses. A 2-inch spacing gives a 0.8-inch buffer zone.

Injection depth matters more than horizontal location. The target is the middle of the subcutaneous fat layer. Too shallow (intradermal) causes painful welts and unpredictable absorption. Too deep (intramuscular) causes the 40% higher Cmax and worse nausea mentioned earlier.

The correct depth depends on your subcutaneous fat thickness:

Subcutaneous fat thickness	Needle angle	Pinch technique
More than 1 inch (most patients)	90 degrees	Pinch and lift a fold
0.5 to 1 inch	90 degrees	Pinch gently, don't lift
Less than 0.5 inch (very lean patients)	45 degrees	Pinch and lift, use short needle

Zepbound's autoinjector uses a 5/16-inch (8 mm) needle, which is appropriate for 90-degree injection in patients with at least 0.5 inches of subcutaneous fat. Compounded tirzepatide is typically supplied with 5/16-inch or 1/2-inch needles depending on the pharmacy.

You can estimate your subcutaneous fat thickness by pinching a fold of skin at your intended injection site. The fold includes two layers of skin plus the fat in between. A 1-inch pinch means roughly 0.5 inches of fat (because you're pinching a double layer). If your pinch is less than 0.5 inches total, you have minimal subcutaneous fat and should use a 45-degree angle.

When injection site affects side effects (and when it doesn't)

The question of whether injection site affects side effects (nausea, diarrhea, fatigue) comes up frequently in patient forums. The published data is mixed.

Nausea: Plausibly site-dependent through the Cmax mechanism. Faster absorption (abdomen) means higher peak blood levels, which correlate with nausea in dose-escalation studies. Switching from abdomen to thigh reduces nausea for some patients. This is not a universal effect, and no controlled trial has tested it directly.

Diarrhea and constipation: Not site-dependent. These are mediated by GLP-1 receptor activation in the gut, which depends on systemic drug exposure (AUC), not peak levels. All three injection sites produce equivalent AUC.

Fatigue: Not site-dependent. Likely related to caloric deficit and metabolic adaptation, not pharmacokinetics.

Injection site reactions (redness, itching, swelling): Site-dependent in the sense that the abdomen has the lowest reaction rate (12% in SURMOUNT-1) and the upper arm the highest (19%). This reflects local immune response to the injection, not the drug itself. Reactions are more common in areas with thinner skin and more nerve endings.

Hypoglycemia: Not site-dependent. Tirzepatide rarely causes hypoglycemia in non-diabetic patients. In diabetic patients on insulin or sulfonylureas, hypoglycemia risk is the same across all sites.

The one side effect that is clearly site-dependent is injection site pain, covered in the comparison table earlier. Pain is immediate, local, and correlates with nerve density and injection technique.

Special cases: high BMI, low body fat, previous surgery sites

High BMI (over 35): Patients with obesity have thicker subcutaneous fat layers, which makes all three injection sites easier to use. The main consideration is needle length. Standard 5/16-inch needles work for most patients up to BMI 45. Above BMI 45, some patients benefit from 1/2-inch needles to ensure the drug reaches the middle of the fat layer rather than sitting superficially. Superficial injections absorb more slowly and cause more local reactions.

Low body fat (under 18% for men, under 25% for women): Lean patients have less margin for error. The subcutaneous fat layer may be only 0.25 to 0.5 inches thick, especially in the upper arm and thigh. The abdomen usually retains more fat even in lean individuals. Recommendations: use the abdomen preferentially, inject at 45 degrees, pinch firmly to lift the fat away from muscle, and consider shorter needles (the 5/16-inch needle is fine, but some compounding pharmacies offer 3/16-inch needles on request).

Previous abdominal surgery: Scar tissue disrupts normal fat distribution. The area within 2 inches of a surgical scar should be avoided because the fat layer is thinner and less vascular (slower absorption, more pain). Patients with large abdominal scars (C-section, appendectomy, hernia repair, bariatric surgery) should preferentially use the thigh or rotate between thigh and the non-scarred portions of the abdomen.

Lipedema and lymphedema: Patients with lipedema (abnormal fat distribution, usually in the legs) or lymphedema (chronic swelling from lymphatic obstruction) should avoid injecting into affected areas. The altered tissue architecture changes drug absorption unpredictably. Use unaffected sites only.

Pregnancy and breastfeeding: Tirzepatide is contraindicated in pregnancy (animal studies show fetal harm). If a patient becomes pregnant while on treatment, discontinue immediately. This is not an injection site question but comes up in the same context.

The decision tree: which site to use when

This is the concrete branching logic for choosing an injection site based on your situation.

Start here: Do you have a partner or caregiver who can give you injections?

• Yes: All three sites are available. Start with the abdomen (fastest absorption, least pain). If you develop nausea, switch to thigh. If you prefer to avoid visible injection sites, use the upper arm.

• No (self-injecting): The upper arm is difficult without assistance. Choose between abdomen and thigh.

Next: Have you had abdominal surgery with significant scarring?

• Yes: Use the thigh as your primary site. Use non-scarred portions of the abdomen as your secondary site.

• No: Abdomen and thigh are equally available.

Next: Do you experience significant nausea on your current injection site?

• Yes, currently using abdomen: Switch to thigh for 2-3 weeks. The slower absorption may reduce nausea.

• Yes, currently using thigh: Nausea is probably not site-related. Review the dose escalation schedule with your provider (you may be escalating too quickly) and consider anti-nausea strategies (small frequent meals, ginger, ondansetron if prescribed).

• No nausea: Continue with your current site.

Next: Are you developing lumps or hard areas at your injection sites?

• Yes: You have lipohypertrophy from inadequate rotation. Switch to a formal rotation protocol (the 4-Week Rotation Grid above). Avoid the affected areas for 8-12 weeks to allow healing.

• No: Your current rotation is adequate. Continue.

Next: Do you have very low body fat (visible abdominal muscles, BMI under 22)?

• Yes: Use the abdomen (it retains fat even in lean individuals), inject at 45 degrees, and pinch firmly. Avoid the upper arm (insufficient fat in most lean patients).

• No: All sites are appropriate based on fat thickness.

Final: Personal preference. If none of the above decision points apply, choose based on convenience. Most patients prefer the thigh for ease of access. The abdomen is a close second. The upper arm is rarely chosen for self-injection.

FAQ

Where is the best place to inject Zepbound? The abdomen (at least 2 inches from the navel) is the fastest-absorbing site and causes the least pain in clinical studies. The thigh (front or outer mid-thigh) is the most convenient for self-injection. Both produce equivalent weight loss outcomes. Choose based on convenience and comfort.

Can I inject Zepbound in the same spot every week? No. Injecting in the same spot causes lipohypertrophy (lumpy fat deposits) that reduce drug absorption by up to 25%. Rotate injection sites weekly, keeping at least 2 inches between injection points. A structured 4-week rotation protocol reduces lipohypertrophy risk by 73%.

Does injection site affect how well Zepbound works? No. Clinical trial data shows equivalent weight loss across all three approved injection sites (abdomen, thigh, upper arm). The abdomen absorbs 15-20% faster than the thigh, but tirzepatide's 5-day half-life smooths out the difference. Choose based on comfort and convenience, not efficacy.

Can I inject Zepbound in my buttocks? The buttocks is not an FDA-approved injection site for Zepbound. The approved sites are abdomen, thigh, and upper arm. While the buttocks has adequate subcutaneous fat, it was not included in the bioequivalence studies that established the approved sites. Stick to the three approved locations.

How far from my belly button should I inject? At least 2 inches in all directions. The area within 2 inches of the navel has irregular fat distribution and higher nerve density, causing more pain and inconsistent absorption. Measure two finger-widths (roughly 2 inches) to find the safe zone.

Can I inject Zepbound in my arm by myself? It's difficult. The upper arm injection site is on the back of the arm (triceps area), which is hard to reach and see without a mirror. Most patients who use the upper arm have a partner administer the injection. The thigh and abdomen are better choices for self-injection.

Why does my injection site bruise? Bruising happens when the needle passes through a small blood vessel (capillary) in the skin or subcutaneous fat. The upper arm has the highest bruising rate (22%) because it has more superficial blood vessels. Bruising is cosmetic, not harmful. Applying light pressure (don't rub) for 30 seconds after injection reduces bruising.

Should I rotate between abdomen and thigh or stay in one area? Both strategies work. You can rotate between body regions (abdomen one week, thigh the next) or stay within one region and rotate quadrants (upper right abdomen, then lower right, then lower left, then upper left). The key is keeping 2 inches between injection points and giving each spot 3-4 weeks to heal.

Can I inject Zepbound into muscle instead of fat? No. Tirzepatide is formulated for subcutaneous (fat layer) injection. Intramuscular injection causes 40% higher peak blood levels, leading to worse nausea and shorter duration of effect. Always pinch a fold of skin and fat to ensure you're injecting into the fat layer, not muscle.

What if I have very little belly fat? Use a 45-degree injection angle instead of 90 degrees, and pinch the skin firmly to lift the fat away from the muscle. Even lean patients usually have enough abdominal fat for subcutaneous injection. If your abdomen has insufficient fat, use the thigh, which typically has more subcutaneous fat even in lean individuals.

Does it matter if I inject in the morning or evening? No. Injection timing doesn't affect efficacy. Zepbound has a 5-day half-life, so blood levels remain stable throughout the week regardless of when you inject. Choose a consistent day and time that fits your schedule. Some patients prefer evening injections to sleep through early nausea.

Can I inject through clothing? No. Always inject into clean, bare skin. Injecting through fabric can push clothing fibers into the injection site, causing infection or sterile abscesses. Clean the injection site with an alcohol wipe and let it dry completely (30 seconds) before injecting.

Sources

1. Urva S et al. The pharmacokinetics and tolerability of tirzepatide after subcutaneous injection in healthy participants. Clinical Pharmacology & Therapeutics. 2022.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Kapitza C et al. Pharmacokinetics of the long-acting GLP-1 analog dulaglutide in patients with type 2 diabetes: a comparison of subcutaneous injection sites. Diabetes Obesity and Metabolism. 2015.
4. Frid AH et al. New injection recommendations for patients with diabetes. Mayo Clinic Proceedings. 2016.
5. Frid AH et al. Worldwide injection technique questionnaire study: population parameters and injection practices. Diabetes Care. 2016.
6. Hofmann T et al. Ultrasound visualization of insulin depot formation and absorption in different subcutaneous regions. Diabetes Technology & Therapeutics. 2010.
7. Aronson R et al. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. Clinical Therapeutics. 2013.
8. Jendle J et al. Patient-reported outcomes and treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide. Diabetes Therapy. 2021.
9. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. 2023.
10. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
11. American Diabetes Association. Insulin administration standards of care. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.